Immune response, phenotyping and molecular graft surveillance in kidney transplant recipients following severe acute respiratory syndrome coronavirus 2 vaccination.

Autor: Ali NM; NYU Langone Transplant Institute, New York, New York, USA.; Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA., Herati RS; Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA., Mehta SA; NYU Langone Transplant Institute, New York, New York, USA.; Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA., Leonard J; NYU Langone Transplant Institute, New York, New York, USA., Miles J; Medical Affairs, CareDx, Inc, Brisbane, California, USA., Lonze BE; NYU Langone Transplant Institute, New York, New York, USA.; Department of Surgery, NYU Grossman School of Medicine, New York, New York, USA., DiMaggio C; Department of Surgery, NYU Grossman School of Medicine, New York, New York, USA., Tatapudi VS; NYU Langone Transplant Institute, New York, New York, USA.; Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA., Stewart ZA; NYU Langone Transplant Institute, New York, New York, USA.; Department of Surgery, NYU Grossman School of Medicine, New York, New York, USA., Alnazari N; NYU Langone Transplant Institute, New York, New York, USA., Neumann HJ; NYU Langone Transplant Institute, New York, New York, USA.; Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA., Thomas J; NYU Langone Transplant Institute, New York, New York, USA., Cartiera K; NYU Langone Transplant Institute, New York, New York, USA., Weldon E; NYU Langone Transplant Institute, New York, New York, USA., Michael J; NYU Langone Transplant Institute, New York, New York, USA., Hickson C; NYU Langone Transplant Institute, New York, New York, USA., Whiteson H; NYU Langone Transplant Institute, New York, New York, USA., Khalil K; NYU Langone Transplant Institute, New York, New York, USA., Stern JM; NYU Langone Transplant Institute, New York, New York, USA.; Department of Surgery, NYU Grossman School of Medicine, New York, New York, USA., Allen JR; Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA., Tuen M; Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA., Gray-Gaillard SL; Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA., Solis SM; Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA., Samanovic MI; Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA., Mulligan MJ; Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA., Montgomery RA; NYU Langone Transplant Institute, New York, New York, USA.; Department of Surgery, NYU Grossman School of Medicine, New York, New York, USA.
Jazyk: angličtina
Zdroj: Transplant infectious disease : an official journal of the Transplantation Society [Transpl Infect Dis] 2023 Dec; Vol. 25 (6), pp. e14122. Date of Electronic Publication: 2023 Sep 14.
DOI: 10.1111/tid.14122
Abstrakt: Background: Understanding immunogenicity and alloimmune risk following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in kidney transplant recipients is imperative to understanding the correlates of protection and to inform clinical guidelines.
Methods: We studied 50 kidney transplant recipients following SARS-CoV-2 vaccination and quantified their anti-spike protein antibody, donor-derived cell-free DNA (dd-cfDNA), gene expression profiling (GEP), and alloantibody formation.
Results: Participants were stratified using nucleocapsid testing as either SARS-CoV-2-naïve or experienced prior to vaccination. One of 34 (3%) SARS-CoV-2 naïve participants developed anti-spike protein antibodies. In contrast, the odds ratio for the association of a prior history of SARS-CoV-2 infection with vaccine response was 18.3 (95% confidence interval 3.2, 105.0, p < 0.01). Pre- and post-vaccination levels did not change for median dd-cfDNA (0.23% vs. 0.21% respectively, p = 0.13), GEP scores (9.85 vs. 10.4 respectively, p = 0.45), calculated panel reactive antibody, de-novo donor specific antibody status, or estimated glomerular filtration rate.
Conclusions: SARS-CoV-2 vaccines do not appear to trigger alloimmunity in kidney transplant recipients. The degree of vaccine immunogenicity was associated most strongly with a prior history of SARS-CoV-2 infection.
(© 2023 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: